Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare ConferenceBusiness Wire • 04/11/23
Amylyx, A Top 5% Biotech Stock, Just Scored A Huge Win In ALS TreatmentInvestors Business Daily • 03/14/23
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsBusiness Wire • 03/13/23
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023Business Wire • 03/07/23
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma ConferenceBusiness Wire • 02/07/23
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALSBusiness Wire • 02/02/23
Amylyx Pharmaceuticals Announces Exclusive AMX0035 Distribution Agreement with Israel-Based NeopharmBusiness Wire • 01/17/23
100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make MiraclesInvestors Business Daily • 12/30/22
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx ConferenceBusiness Wire • 11/22/22
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The HelmInvestors Business Daily • 11/16/22
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022Business Wire • 11/03/22
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks VideoPRNewsWire • 10/18/22
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness Wire • 10/11/22
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockBusiness Wire • 10/07/22